Southern California Acute Care Facility Standardizes System-wide to Improve Patient Care
IRVINE, Calif., Aug 10, 2010 /PRNewswire via COMTEX/ --
San Antonio Community Hospital (SACH) in Upland, California, andMasimo (Nasdaq: MASI), the inventor of Masimo rainbow Pulse CO-Oximetry(TM), Masimo rainbow Acoustic Monitoring(TM), and Masimo SET(R) Measure-Through Motion and Low Perfusion pulse oximetry, today jointly announced the completion of San Antonio Community Hospital's system-wide conversion to Masimo rainbow technology. The conversion ensures that all SACH patients will be monitored using the most technologically and clinically-advanced noninvasive patient monitoring technologies available--providing real-time measurement results for critical physiological parameters that help clinicians to more rapidly assess, diagnose, and treat patients.
"We converted our entire network to Masimo's advanced oximetry technology platform to give our clinical team the superior tools they need to provide the best clinical care possible and, after careful evaluation, it became clear that we would also be lowering our overall costs by implementing Masimo rainbow SET," stated Steven Moreau, President and CEO of San Antonio Community Hospital. "Staying on the forefront of medical technology advancements is just one of the ways SACH is staying true to our mission of providing outstanding healthcare in the community."
The system-wide conversion standardizes all of SACH's sites of care, including 279 hospital beds, to Masimo rainbow technology--the only upgradable pulse oximetry platform that allows hospitals to add breakthrough noninvasive blood constituent, hemodynamic, and respiration measurement capabilities that previously required invasive procedures. The ability to continuously and noninvasively measure total hemoglobin (SpHb(R)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), Pleth Variability Index (PVI(R)), and acoustic respiration rate (RRa(TM)), in addition to Masimo SET 'gold standard' Measure-Through Motion and Low Perfusion oxyhemoglobin (SpO2), perfusion index (PI), and pulse rate (PR) measurements enables monitoring of multiple physiological parameters simultaneously--facilitating earlier detection and treatment of life-threatening conditions. The conversion involved upgrading virtually all of the hospital's multiparameter patient monitors, oximeters, and sensors to enable the new patient monitoring capabilities.
Perry Chu, MD, Anesthesiologist at San Antonio Community Hospital, stated, "Masimo's oximeters have proven to be the most sensitive and reliable, picking up saturation levels even in low perfusion states and when the patient is cold. I am particularly impressed with the Radical-7's ease-of-use, portability, and range of clinical utility as it affords us the unique ability to noninvasively monitor hemoglobin levels more closely and tightly."
Masimo Founder and CEO, Joe Kiani, stated, "San Antonio Community Hospital's conversion to the Masimo rainbow technology platform is proof positive of their commitment to offering the most advanced patient care throughout the Inland Empire."
About Masimo
Masimo (NASDAQ: MASI) develops innovative monitoring technologies that significantly improve patient care--helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET(R), which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow Pulse CO-Oximetry(TM), allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb(R)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and Pleth Variability Index (PVI(R)), in addition to SpO2, pulse rate, and perfusion index (PI). In 2009, Masimo introduced rainbow Acoustic Monitoring(TM), the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa(TM)). Masimo's rainbow platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care...by Taking Noninvasive Monitoring to New Sites and Applications(R)." Additional information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our belief that Masimo SET and Masimo rainbow SET oximetry technologies will provide sufficient sensitivity and specificity to accurately detect physiological abnormalities and potentially life-threatening conditions in real-time for all patients, risks related to our belief that Masimo technologies and measurements will help clinicians to more rapidly assess, diagnose, and treat patients, risks related to our assumptions regarding the repeatability of clinical results, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Media Contacts:
Dana Banks Lisa Ciccanti
Masimo Corporation San Antonio Community Hospital
(949) 297-7348 (909) 920-4740
dbanks@masimo.com lciccanti@sach.org
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, and SEDLine are trademarks or registered trademarks of Masimo Corporation.
SOURCE Masimo